Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions

Brain Research Reviews

Volumn 31, Issue 2-3, 2000, Pages 277-287

  Schwartz, Jean Charles ^a   Diaz, Jorge ^b   Pilon, Catherine ^a   Sokoloff, Pierre ^a  

^a CENTRE PAUL BROCA   (France)

^b FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

Behavioural sensitization; Brain development; Molecular genetics; Neuroleptics; Nucleus accumbens; Schizophrenia

Indexed keywords

AMISULPRIDE; AMPEROZIDE; CARPIPRAMINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; ILOPERIDONE; LEVODOPA; NEUROLEPTIC AGENT; PIMOZIDE; PIPOTIAZINE; PROCHLORPERAZINE; RACLOPRIDE; RECOMBINANT RECEPTOR; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SULPIRIDE; SULTOPRIDE; THIORIDAZINE;

ANIMAL MODEL; BEHAVIOR; BRAIN CORTEX; BRAIN DEVELOPMENT; BRAIN REGION; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; DNA SEQUENCE; DRUG RECEPTOR BINDING; DRUG TOLERANCE; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; LIMBIC SYSTEM; MOLECULAR GENETICS; NERVE CELL NETWORK; NEUROEPITHELIUM; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RODENT; SCHIZOPHRENIA; SENSITIZATION; TISSUE DISTRIBUTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; HUMANS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA;

EID: 0034055689     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(99)00043-0     Document Type: Conference Paper

References (76)

1. Angrist B., Sathananthan G., Wilk S., Gershon S. Amphetamine psychosis: behavioral and biochemical aspects. J. Psychiatr. Res. 11:1974;13-23.
2. 3 receptor as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. USA. 94:1997;3363-3367.
3. 2 receptor mRNA. Brain Res. 564:1991;203-219.
4. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. 20:1963;140-144.
5. Coon H., Byerley W., Holik J., Hoff M., Myles-Worsley M., Lannfelt L., Sokoloff P., Schwartz J.C., Waldo M., Freedman R., Plaetke R. Linkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees. Am. J. Hum. Genet. 52:1993;327-334.
6. 3 receptor gene. J. Med. Genet. 29:1992;858-860.
7. 3 receptors in the mouse brain: autoradiographic evidence for a transient cortical expression. Dev. Brain Res. 94:1996;166-174.
8. Deutch A.Y. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J. Neural Transm. 91:1993;197-221.
9. 3 receptors on neurotensin mRNA expression in nucleus accumbens. Eur. J. Neurosci. 6:1994;1384-1387.
10. 3 receptor. Neuroscience. 65:1995;731-745.
11. 3 receptor mRNA in proliferative zones during embryonic development of the rat brain. J. Neurosci. 17:1997;4282-4292.
12. 3 receptor gene is associated with opioid dependence. Mol. Psychiatry. 3:1998;333-336.
13. 3 gene and schizophrenia: ethnic heterogeneity and significant association in caucasians. Am. J. Med. Genet. [Neuropsychiatric Genetics]. 81:1998;318-322.
14. 2 dopamine receptor subtype mRNA levels in the brain. FEBS Lett. 339:1994;63-66.
15. 3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J. Neurosci. 16:1996;2020-2026.
16. Freeman T.B., Spence M.S., Boss B.D., Spector D.H., Strecker R.E., Olanow C.W., Kordower J.H. Development of dopaminergic neurons in the human substantia nigra. Exp. Neurol. 113:1991;344-353.
17. Gingrich J.A., Caron M.G. Recent advances in the molecular biology of dopamine receptors. Annu. Rev. Neurosci. 16:1993;299-321.
18. Glenthoj B.Y., Hemmingsen R. Dopaminergic sensitization: implications for the pathogenesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 21:1997;23-46.
19. 3 receptor gene: organization, transcript variants and polymorphism associated with schizophrenia. Am. J. Med. Genet. [Neuropsychiatric Genetics]. 67:1996;58-70.
20. 3 receptor. J. Neural. Transm. 103:1996;1166-1175.
21. 3H-N-propylnorapomorphine in mouse striatum and tuberculum olfactorium. Naunyn Schmiedeberg's Arch. Pharmacol. 329:1985;117-122.
22. Guo N., Klitenick M.A., Tham C.S., Fibiger H.C. Receptor mechanisms mediating clozapine-induced c-fos expression in the forebrain. Neuroscience. 65:1995;747-756.
23. 3 receptors and use of antipsychotics in patients with schizophrenia. Arch. Gen. Psychiatry. 54:1997;225-232.
24. 3H]PD 128907. Psychopharmacology. 128:1996;240-247.
25. Iwanami A., Sugiyama A., Kuroki N., Toda S., Kato N., Nakatani Y., Horita N., Kaneko T. Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report. Acta Psychiatr. Scand. 89:1994;428-432.
26. Janowsky D.S., Davis J.M. Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms. Arch. Gen. Psychiatry. 33:1976;304-308.
27. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Rev. 16:1991;223-244.
28. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch. Gen. Psychiatry. 54:1997;567-572.
29. 3 receptor gene variants and substance abuse in schizophrenia. Mol. Psychiatry. 3:1998;337-341.
30. 2-family receptor distribution in human postmortem tissue: an autoradiographic study. Neuroreport. 6:1995;2505-2512.
31. 3 receptor sites in rat brain: a comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur. J. Neurosci. 5:1993;145-153.
32. 3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr. Genet. 2:1992;249-256.
33. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. USA. 93:1996;9235-9240.
34. 3 dopamine receptor gene. Hum. Genet. 87:1991;618-620.
35. 2 dopamine receptors. Neuroscience. 73:1996;131-143.
36. 3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl. Acad. Sci. USA. 92:1995;1719-1723.
37. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 91:1987;415-433.
38. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology. 17:1997;205-229.
39. Lipska B.K., Weinberger D.R. Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacol. 10:1994;199-205.
40. 3 receptor with the Semliki virus system. Biochem. Biophys. Res. Comm. 225:1996;1068-1072.
41. 4 using haplotype relative risk. Hum. Hered. 44:1994;328-336.
42. 3 receptors. Mol. Pharmacol. 43:1993;749-754.
43. McGuffin P., Owen M.J., Farmer A.E. Genetic basis of schizophrenia. Lancet. 346:1995;678-682.
44. Meador-Woodruff J.H., Grandy D.K., Van Tol H.H.M., Damask S.P., Little K.Y., Civelli O., Watson S.J. Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology. 10:1994;239-248.
45. Meador-Woodruff J.H., Haroutunian V., Powchik P., Davidson M., Davis K.L., Watson S.J. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Arch. Gen. Psychiatry. 54:1997;1089-1095.
46. Miller J.C., Friedhoff A.J. Prenatal neuroleptic exposure alters postnatal striatal cholinergic activity in the rat. Dev. Neurosci. 8:1986;111-116.
47. 3 receptors. Eur. J. Pharmacol. 6:1993;121-125.
48. 3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur. J. Neurosci. 10:1998;2565-2573.
49. 2 receptors to mesostriatal regions of human forebrain. Proc. Natl. Acad. Sci. USA. 91:1994;11271-11275.
50. Pennartz C.M., Groenewegen H.J., Lopes da Silva F.H. The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. Prog. Neurobiol. 42:1994;719-761.
51. 3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur. J. Pharmacol. [Mol. Pharmacol. Sect.]. 268:1994;129-139.
52. Roberts G.W. Schizophrenia: a neuropathological perspective. Br. J. Psychiatry. 158:1991;8-17.
53. Rosengarten H., Fridhoff A.J. Enduring changes in dopamine receptor cells of pups from drug administration to pregnant and nursing rats. Science. 203:1979;1133-1135.
54. Ross C.A., Pearlson G.D. Schizophrenia, the heteromodal association neocortex and development: potential for a neurogenetic approach. Trends Neurosci. 19:1996;717-726.
55. 3 receptor gene-expressed variant and schizophrenia. Am. J. Med. Genet. 67:1996;232-234.
56. 3 receptor gene and schizophrenia. Am. J. Psychiatry. 151:1994;107-111.
57. Sato M., Numachi Y., Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr. Bull. 18:1992;115-122.
58. 3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc. Natl. Acad. Sci. USA. 90:1993;8942-8946.
59. Schwartz J.C., Costentin J., Martres M.P., Protais P., Baudry M. Modulation of receptor mechanisms in the CNS: hyper- and hyposensitivity to catecholamines. Neuropharmacology. 17:1978;665-685.
60. 3 receptor coexistence. Brain Res. Rev. 26:1998;236-242.
61. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
62. 3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Mol. Brain Res. 45:1997;335-339.
63. Snyder S.H. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am. J. Psychiatry. 133:1976;197-202.
64. 2 receptor. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 225:1992;331-337.
65. 3) as a target for neuroleptics. Nature. 347:1990;146-151.
66. Sokoloff P., Schwartz J.C. The novel dopamine receptors half a decade later. Trends Pharmacol. Sci. 16:1995;270-275.
67. 3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J. Neurosci. 16:1996;6100-6106.
68. Sung C.H., Schneider B.G., Agarwal N., Papermaster D.S., Nathans J. Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Proc. Natl. Acad. Sci. USA. 88:1991;8840-8844.
69. 3 dopamine receptor mRNA is widely expressed in the human brain, Brain Res. (1998) in press.
70. Tarazi F.I., Florijn W.J., Creese I. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience. 78:1997;985-996.
71. Voorn P., Kalsbeek A., Jorritsma-Byham B., Groenewegen H.J. The pre- and post-natal development of the dopaminergic cell group in the developmental mesencephalon and the dopaminergic innervation of the striatum of the rat. Neuroscience. 25:1988;857-887.
72. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry. 44:1987;660-669.
73. D.R. Weinberger, Neurodevelopmental perspectives in schizophrenia, in: F.E. Bloom, D.J. Kupfer (Eds), Psychopharmacology: The Fourth Generation of Progress, Raven Press, New York, 1995, pp. 1171-1183.
74. 3 dopamine receptor gene locus in icelandic pedigrees. Psychiatry Res. 46:1993;253-259.
75. 3 receptor gene and schizophrenia. Mol. Psychiatry. 3:1998;141-149.
76. Zahm D.S., Brog J.S. On the significance of subterritories in the 'accumbens' part of the rat ventral striatum. Neuroscience. 50:1992;751-767.